UCB’s Keppra XR Wins FDA Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Extended-release tabs set to beat Keppra generics to pharmacy shelves.
You may also be interested in...
Older Primary Care Drugs Matter – For Cash, And For Emerging Market Access
Europe's mid-sized pharma may be going specialist like much of the rest of the industry, including some of the biggest companies
Prevacid, Topamax Among Blockbusters Set To Lose Exclusivity In ’09
At least four blockbuster drugs could face generic rivals in the U.S. for the first time in 2009
Prevacid, Topamax Among Blockbusters Set To Lose Exclusivity In ’09
At least four blockbuster drugs could face generic rivals in the U.S. for the first time in 2009